GoldenGolden
Advanced Search
AlloVir

AlloVir

AlloVir (formerly ViraCyte) is a company that develops cell therapies for patients suffering from life-threatening virus-associated diseases.

AlloVir is working on the clinical development of novel cell therapies designed to restore T-cell immunity against virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients. AlloVir built a technology platform developed by researchers at Baylor College of Medicine's Center for Cell and Gene Therapy.

Development of their cell therapies involves exposing donor T cells to secreted proteins called cytokines combined with viral fragments so that the immune cells learn to recognize and eliminate certain pathogens. Their therapy Viralym-M (ALVR105) aims to be an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens: Viralym-M completed phase 2 clinical trials in 2014.

ALVR106 is an allogenic off-the-shelf multi-virus specific T-cell therapy in development that targets four common community-acquired respiratory viruses which are respiratory syncytial virus, influenza, parainfluenza virus and human meta-pneumovirus.

Using the approach used for Viralym-M, AlloVir and Baylor College of Medicine are working together to develop an off-the-shelf therapy capable of targeting the COVID-19 causing virus, SARS-CoV-2 and potentially be effective against other similar viruses such as SARS-CoV, MERS-CoV and endemic coronaviruses. SARS-CoV-2-specific T cells are planned as a monotherapy and coronaviruses are planned to be incorporated into a preclinical stage therapy, ALVR106, aimed at community-acquired respiratory viruses. Viralym-M expects the therapy would improve outcomes for immunocompromised patients exposed to SARS-CoV-2 and other viruses.

Timeline

May 22, 2019
AlloVir joined ElevateBio protfolio.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
March 23, 2021
FierceBiotech
After she helped Gilead Sciences repurpose its old Ebola drug remdesivir into the first antiviral for COVID-19, AlloVir is hoping Diana Brainard, M.D., can repeat that same magic as its new CEO.
Darrell Etherington
March 15, 2021
TechCrunch
ElevateBio, one of the leading biotech companies focused on gene-based therapies has raised a massive $525 million Series C round of financing, more than doubling the company's $193 million Series B funding which closed last year. This new funding comes from existing investor Matrix Capital Management, and also adds new investors SoftBank and Fidelity Management [...]
Amirah Al Idrus
March 15, 2021
FierceBiotech
After launching multiple companies and signing some partners, ElevateBio is grabbing another $525 million to fuel its work in cell and gene therapy. The funds will bolster its technology and manufacturing capacity and bankroll more partnerships as it works on its own pipeline.
Ben Adams
July 7, 2020
FierceBiotech
Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.